About Recursion pharmaceuticals
Recursion Pharmaceuticals: Revolutionizing Drug Discovery through Digital Biology
Recursion Pharmaceuticals is a biotechnology company that is reengineering drug discovery through digital biology. The company's mission is to discover transformative new treatments by combining automation, machine learning, in vivo validation, and a highly cross-functional team. Recursion Pharmaceuticals was founded in 2013 by Chris Gibson, Blake Borgeson, and Dean Li.
The company's approach to drug discovery involves using artificial intelligence (AI) and machine learning algorithms to analyze vast amounts of biological data. This data includes images of cells and tissues that are collected using high-throughput microscopy techniques. By analyzing this data with AI algorithms, Recursion Pharmaceuticals can identify potential drug candidates more quickly and accurately than traditional methods.
One of the key advantages of Recursion Pharmaceuticals' approach is its ability to identify drugs for rare diseases that have been historically difficult to treat. By analyzing large amounts of biological data from patients with rare diseases, the company can identify potential drug candidates that may have been overlooked by traditional methods.
In addition to its use of AI and machine learning algorithms, Recursion Pharmaceuticals also employs a highly cross-functional team that includes experts in biology, chemistry, engineering, computer science, and other fields. This interdisciplinary approach allows the company to tackle complex problems from multiple angles and develop innovative solutions.
Another important aspect of Recursion Pharmaceuticals' approach is its use of in vivo validation. This means testing potential drug candidates on living organisms rather than just in vitro or computer simulations. By doing so, the company can better understand how these drugs will behave in real-world situations.
Recursion Pharmaceuticals has already made significant progress towards discovering new treatments for a variety of diseases. In 2020 alone, the company announced partnerships with Bayer AG and Takeda Pharmaceutical Company Limited aimed at developing new therapies for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH).
Overall, Recursion Pharmaceuticals represents an exciting new frontier in drug discovery. Its use of AI algorithms combined with a highly cross-functional team has already yielded promising results towards developing new treatments for rare diseases as well as more common conditions like fibrotic diseases."